Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/16b408c9-40d3-4693-b860-7aa98f1d0c45/

BVS

Bioventus Inc
Chart
11.80 USD
Latest Week 2026-07-24
HealthcareMedical DevicesSMALL
Snapshot 2026-07-26 · 0.6w · Fresh
0.93
OS Score
66.0%
Value
95.0%
Quality
89.0%
Momentum
7/9
F-Score
0.792
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
7 of 23 passing
★
OS Composite
OS 0.930
↗
Trending Value
✗
◆
Quality × Value
QV 0.792
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
9.6%
◐
Veiled Value
✗
▣
Piotroski Bargains
F7
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 49%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
Val 66%
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
RAM 1.12
V
Value Analysis
Cheapness relative to fundamentals
66.0%ile
P/E
28.1×
P/S
1.4×
P/B
4.2×
E/P
0.0527
FCF Yield
0.097
EBITDA/EV
0.096
SH Yield
-0.003
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
35.00000000
/100 — 1=cheapest
VC2 (Trending Value)
71.00000000
/100
VC3 (Buyback)
30.00000000
/100
FCF yield of 9.7% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
95.0%ile
ROE
0.151
ROA
0.044
Net Margin
0.049
Op Margin
0.099
GPA
0.600
D/E
2.20
Current
1.69
F-Score
7/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.015
Stability
19.650
lower=better
Accruals
-0.114
lower=better
5yr Consist
No
Highly leveraged with D/E of 2.20 — returns are being amplified by debt.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
89.0%ile
6M Return
47.1%
12M Return
79.6%
12-1 Mom
48.9%
Risk-Adj
1.12
Vol 252d
43.5%
Vol 60d
98.6%
↑ Expanding
Max DD 12M
-19.6%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 49% is very strong — a clear uptrend. Near-term vol (99%) is expanding vs long-term (44%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.93
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
80.2%
Sector Quality %ile
94.4%
P/E z-score
0.02
P/B z-score
-0.11
Sector Avg OS
64.8%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
PBYI Puma Biotechnology Inc 97.0% 79.0% 97.0% 96.0%
Factor Interactions
Hot but Volatile
Strong momentum (89th) but high volatility (44%). Momentum could reverse sharply.
Leveraged Returns
Strong ROE (15%) boosted by high leverage (D/E 2.2). Returns look good but come with balance sheet risk.
Volatility Expanding
60-day vol (99%) significantly exceeds 252-day (44%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
52.4% avg (7 factors)
Quality
C
54.1% avg (8 factors)
Momentum
A
87.0% avg (4 factors)
Risk
D
44.1% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.930—8—
Value %ile0.660—0—
Quality %ile0.950—8—
Momentum %ile0.890—4—
F-Score7.000—8—
Confidence0.871—8—
Volatility0.435—8—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
28.07
Earnings Yield (E/P)
0.0527
Price / Sales
1.39
Price / Book
4.23
Price / Cash Flow
7.77
FCF Yield
9.7%
EBITDA / EV
9.6%
Sales Yield (1/P·S)
0.5331
Shareholder Yield
Div + net buyback / mktcap
-0.3%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
15.1%
Return on Assets
4.4%
Net Margin
4.9%
Operating Margin
9.9%
Gross Profit / Assets
Novy-Marx GPA
60.0%
Debt / Equity
2.20
Current Ratio
1.69
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.114
MomentumPrice trend strength over different horizons
6M Return
47.1%
12M Return
79.6%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
48.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
1.12
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
1.5%
Earnings Stability (CV)
Lower = more stable
19.650
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
7
Buyback Yield
-0.3%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
35
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
71
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
30
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity